FIELD: cell biology; medicine.
SUBSTANCE: present invention relates to cell biology and medicine, in particular to constructed T-cells, their production methods, a pharmaceutical composition, a vector for construction of T-cells, and the use of the latter for the treatment of cancer. To produce a constructed human T-cell, TCR-inhibiting molecule (TIM) is expressed in the specified T-cell, which is encoded by a nucleic acid sequence selected from SEQ ID No: 80, 82, 84, or 86.
EFFECT: present invention allows for an increase in the efficiency of remedies based on T-cells for the treatment of cancer.
14 cl, 3 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| METHODS FOR CONSTRUCTING HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2725542C2 |
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
